Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 433 entries
Sorted by: Best Match Show Resources per page
Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative.

Cancer cell international

Reynisson J, Jaiswal JK, Barker D, D'mello SA, Denny WA, Baguley BC, Leung EY.
PMID: 26966420
Cancer Cell Int. 2016 Mar 10;16:18. doi: 10.1186/s12935-016-0293-6. eCollection 2016.

BACKGROUND: The thieno[2,3-b]pyridines were discovered by virtual high throughput screening as potential inhibitors of phospholipase C (PLC) isoforms and showed potent growth inhibitory effects in National Cancer Institute's human tumour cell line panel (NCI60). The mechanism of the anti-proliferative...

Cite
Reynisson J, Jaiswal JK, Barker D, et al. Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell Int. 2016;16:18doi: 10.1186/s12935-016-0293-6.
Reynisson, J., Jaiswal, J. K., Barker, D., D'mello, S. A., Denny, W. A., Baguley, B. C., & Leung, E. Y. (2016). Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer cell international, 1618. https://doi.org/10.1186/s12935-016-0293-6
Reynisson, Jóhannes, et al. "Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative." Cancer cell international vol. 16 (2016): 18. doi: https://doi.org/10.1186/s12935-016-0293-6
Reynisson J, Jaiswal JK, Barker D, D'mello SA, Denny WA, Baguley BC, Leung EY. Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell Int. 2016 Mar 10;16:18. doi: 10.1186/s12935-016-0293-6. eCollection 2016. PMID: 26966420; PMCID: PMC4785615.
Copy Download .nbib Format: NLM
Synthesis and Self-Assembly of a Mikto-Arm Star Dual Drug Amphiphile Containing both Paclitaxel and Camptothecin.

Journal of materials chemistry. B

Cheetham AG, Zhang P, Lin YA, Lin R, Cui H.
PMID: 25667746
J Mater Chem B. 2014 Nov 14;2(42):7316-7326. doi: 10.1039/C4TB01084A.

Self-assembly of anticancer therapeutics into discrete nanostructures provides an innovative way to develop a self-delivering nanomedicine with a high, quantitative drug loading. We report here the synthesis and assembly of a mikto-arm star dual drug amphiphile (DA) containing both...

Cite
Cheetham AG, Zhang P, Lin YA, et al. Synthesis and Self-Assembly of a Mikto-Arm Star Dual Drug Amphiphile Containing both Paclitaxel and Camptothecin. J Mater Chem B. 2014;2(42):7316-7326doi: 10.1039/C4TB01084A.
Cheetham, A. G., Zhang, P., Lin, Y. A., Lin, R., & Cui, H. (2014). Synthesis and Self-Assembly of a Mikto-Arm Star Dual Drug Amphiphile Containing both Paclitaxel and Camptothecin. Journal of materials chemistry. B, 2(42), 7316-7326. https://doi.org/10.1039/C4TB01084A
Cheetham, A G, et al. "Synthesis and Self-Assembly of a Mikto-Arm Star Dual Drug Amphiphile Containing both Paclitaxel and Camptothecin." Journal of materials chemistry. B vol. 2,42 (2014): 7316-7326. doi: https://doi.org/10.1039/C4TB01084A
Cheetham AG, Zhang P, Lin YA, Lin R, Cui H. Synthesis and Self-Assembly of a Mikto-Arm Star Dual Drug Amphiphile Containing both Paclitaxel and Camptothecin. J Mater Chem B. 2014 Nov 14;2(42):7316-7326. doi: 10.1039/C4TB01084A. PMID: 25667746; PMCID: PMC4319564.
Copy Download .nbib Format: NLM
1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates .

Oncology letters

Yang PS, Wang JJ, Wang YH, Jan WC, Cheng SP, Hsu YC.
PMID: 27123150
Oncol Lett. 2016 May;11(5):3551-3557. doi: 10.3892/ol.2016.4430. Epub 2016 Apr 07.

1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane (DPD), a diamantane derivative, was previously noted as an anticancer compound through anticancer drug screening with NCI-60 human tumor cells. Irinotecan (CPT-11), a semisynthetic derivative of camptothecin, is clinically active in the treatment of colorectal cancer, with...

Cite
Yang PS, Wang JJ, Wang YH, et al. 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates . Oncol Lett. 2016;11(5):3551-3557doi: 10.3892/ol.2016.4430.
Yang, P. S., Wang, J. J., Wang, Y. H., Jan, W. C., Cheng, S. P., & Hsu, Y. C. (2016). 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates . Oncology letters, 11(5), 3551-3557. https://doi.org/10.3892/ol.2016.4430
Yang, Po-Sheng, et al. "1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates ." Oncology letters vol. 11,5 (2016): 3551-3557. doi: https://doi.org/10.3892/ol.2016.4430
Yang PS, Wang JJ, Wang YH, Jan WC, Cheng SP, Hsu YC. 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates . Oncol Lett. 2016 May;11(5):3551-3557. doi: 10.3892/ol.2016.4430. Epub 2016 Apr 07. PMID: 27123150; PMCID: PMC4840989.
Copy Download .nbib Format: NLM
Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer.

Quantitative imaging in medicine and surgery

Choi J, Kim H, Choi Y.
PMID: 26682135
Quant Imaging Med Surg. 2015 Oct;5(5):656-64. doi: 10.3978/j.issn.2223-4292.2015.08.09.

BACKGROUND: Triple-negative breast cancer (TNBC) is a highly diverse group of cancers characterized by tumors that does not express estrogen and progesterone receptors, as well as human epidermal growth factor receptor 2 (HER2) gene expression. TNBC is associated with...

Cite
Choi J, Kim H, Choi Y. Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer. Quant Imaging Med Surg. 2015;5(5):656-64doi: 10.3978/j.issn.2223-4292.2015.08.09.
Choi, J., Kim, H., & Choi, Y. (2015). Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer. Quantitative imaging in medicine and surgery, 5(5), 656-64. https://doi.org/10.3978/j.issn.2223-4292.2015.08.09
Choi, Jaehee, et al. "Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer." Quantitative imaging in medicine and surgery vol. 5,5 (2015): 656-64. doi: https://doi.org/10.3978/j.issn.2223-4292.2015.08.09
Choi J, Kim H, Choi Y. Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer. Quant Imaging Med Surg. 2015 Oct;5(5):656-64. doi: 10.3978/j.issn.2223-4292.2015.08.09. PMID: 26682135; PMCID: PMC4671977.
Copy Download .nbib Format: NLM
Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer.

Translational lung cancer research

Zarogoulidis P, Darwiche K, Kalamaras G, Huang H, Hohenforst-Schmidt W, Zarogoulidis K.
PMID: 25806211
Transl Lung Cancer Res. 2013 Feb;2(1):E17-22. doi: 10.3978/j.issn.2218-6751.2012.12.07.

Lung cancer long term survival still remains poor and early detection is still the best methodology to treatment. Therefore several novel approaches have been investigated for anticancer drug administration. Inhaled therapies for lung diseases are used since the ancient...

Cite
Zarogoulidis P, Darwiche K, Kalamaras G, et al. Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer. Transl Lung Cancer Res. 2013;2(1):E17-22doi: 10.3978/j.issn.2218-6751.2012.12.07.
Zarogoulidis, P., Darwiche, K., Kalamaras, G., Huang, H., Hohenforst-Schmidt, W., & Zarogoulidis, K. (2013). Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer. Translational lung cancer research, 2(1), E17-22. https://doi.org/10.3978/j.issn.2218-6751.2012.12.07
Zarogoulidis, Paul, et al. "Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer." Translational lung cancer research vol. 2,1 (2013): E17-22. doi: https://doi.org/10.3978/j.issn.2218-6751.2012.12.07
Zarogoulidis P, Darwiche K, Kalamaras G, Huang H, Hohenforst-Schmidt W, Zarogoulidis K. Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer. Transl Lung Cancer Res. 2013 Feb;2(1):E17-22. doi: 10.3978/j.issn.2218-6751.2012.12.07. PMID: 25806211; PMCID: PMC4367653.
Copy Download .nbib Format: NLM
FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.

American journal of translational research

Ling X, Liu X, Zhong K, Smith N, Prey J, Li F.
PMID: 26692923
Am J Transl Res. 2015 Oct 15;7(10):1765-81. eCollection 2015.

Irinotecan and topotecan are the only camptothecin analogues approved by the FDA for cancer treatment. However, inherent and/or acquired irinotecan and topotecan resistance is a challenging issue in clinical practice. In this report, we showed that FL118, a novel...

Cite
Ling X, Liu X, Zhong K, et al. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res. 2015;7(10):1765-81
Ling, X., Liu, X., Zhong, K., Smith, N., Prey, J., & Li, F. (2015). FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. American journal of translational research, 7(10), 1765-81.
Ling, Xiang, et al. "FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models." American journal of translational research vol. 7,10 (2015): 1765-81.
Ling X, Liu X, Zhong K, Smith N, Prey J, Li F. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res. 2015 Oct 15;7(10):1765-81. eCollection 2015. PMID: 26692923; PMCID: PMC4656756.
Copy Download .nbib Format: NLM
The relevance of drug sequence in combination chemotherapy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Shah MA, Schwartz GK.
PMID: 11498402
Drug Resist Updat. 2000 Dec;3(6):335-356. doi: 10.1054/drup.2000.0165.

The concept of combining chemotherapeutic agents to increase the cytotoxic efficacy has evolved greatly over the past several years. In the past, the rationale for combination chemotherapy centered on attacking different biochemical targets, overcoming drug resistance in heterogenous tumors,...

Cite
Shah MA, Schwartz GK. The relevance of drug sequence in combination chemotherapy. Drug Resist Updat. 2000;3(6):335-356doi: 10.1054/drup.2000.0165.
Shah, M. A., & Schwartz, G. K. (2000). The relevance of drug sequence in combination chemotherapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 3(6), 335-356. https://doi.org/10.1054/drup.2000.0165
Shah, Manish A., and Schwartz, Gary K.. "The relevance of drug sequence in combination chemotherapy." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 3,6 (2000): 335-356. doi: https://doi.org/10.1054/drup.2000.0165
Shah MA, Schwartz GK. The relevance of drug sequence in combination chemotherapy. Drug Resist Updat. 2000 Dec;3(6):335-356. doi: 10.1054/drup.2000.0165. PMID: 11498402.
Copy Download .nbib Format: NLM
Clinical Use of Irinotecan: Current Status and Future Considerations.

The oncologist

Saltz LB.
PMID: 10388075
Oncologist. 1997;2(6):402-409.

Irinotecan (CPT-11, Camptosar), a semisynthetic, water-soluble derivative of the plant alkaloid camptothecin, is a drug which has undergone extensive clinical investigation worldwide. It is, at this time, commercially available in the United State for the treatment of fluorouracil-refractory colorectal...

Cite
Saltz LB. Clinical Use of Irinotecan: Current Status and Future Considerations. Oncologist. 1997;2(6):402-409
Saltz, L. B. (1997). Clinical Use of Irinotecan: Current Status and Future Considerations. The oncologist, 2(6), 402-409.
Saltz. "Clinical Use of Irinotecan: Current Status and Future Considerations." The oncologist vol. 2,6 (1997): 402-409.
Saltz LB. Clinical Use of Irinotecan: Current Status and Future Considerations. Oncologist. 1997;2(6):402-409. PMID: 10388075.
Copy Download .nbib Format: NLM
Liposomal delivery of camptothecins.

Pharmaceutical science & technology today

Emerson DL.
PMID: 10840391
Pharm Sci Technol Today. 2000 Jun;3(6):205-209. doi: 10.1016/s1461-5347(00)00268-6.

The use of liposomal drug delivery systems to improve the therapeutic index of pharmaceutical agents is exemplified by camptothecin-based drugs. This highly active class of anticancer agents possesses a unique mechanism of action with some inherent shortcomings, which might...

Cite
Emerson DL. Liposomal delivery of camptothecins. Pharm Sci Technol Today. 2000;3(6):205-209doi: 10.1016/s1461-5347(00)00268-6.
Emerson, D. L. (2000). Liposomal delivery of camptothecins. Pharmaceutical science & technology today, 3(6), 205-209. https://doi.org/10.1016/s1461-5347(00)00268-6
Emerson. "Liposomal delivery of camptothecins." Pharmaceutical science & technology today vol. 3,6 (2000): 205-209. doi: https://doi.org/10.1016/s1461-5347(00)00268-6
Emerson DL. Liposomal delivery of camptothecins. Pharm Sci Technol Today. 2000 Jun;3(6):205-209. doi: 10.1016/s1461-5347(00)00268-6. PMID: 10840391.
Copy Download .nbib Format: NLM
Analysis of comptothecin resistance in yeast: relevance to cancer therapy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Benedetti P, Benchokroun Y, Houghton PJ, Bjornsti MA.
PMID: 17092803
Drug Resist Updat. 1998;1(3):176-83. doi: 10.1016/s1368-7646(98)80037-x.

The budding yeast Saccharomyces cerevisiae is a well defined genetic system to investigate various aspects of camptothecin (Cpt)-induced cytotoxicity. This antineoplastic agent and its derivatives specifically poison eukaryotic DNA topoisomerase I, the product of the TOP1 gene, by stabilizing...

Cite
Benedetti P, Benchokroun Y, Houghton PJ, et al. Analysis of comptothecin resistance in yeast: relevance to cancer therapy. Drug Resist Updat. 1998;1(3):176-83doi: 10.1016/s1368-7646(98)80037-x.
Benedetti, P., Benchokroun, Y., Houghton, P. J., & Bjornsti, M. A. (1998). Analysis of comptothecin resistance in yeast: relevance to cancer therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 1(3), 176-83. https://doi.org/10.1016/s1368-7646(98)80037-x
Benedetti, P, et al. "Analysis of comptothecin resistance in yeast: relevance to cancer therapy." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 1,3 (1998): 176-83. doi: https://doi.org/10.1016/s1368-7646(98)80037-x
Benedetti P, Benchokroun Y, Houghton PJ, Bjornsti MA. Analysis of comptothecin resistance in yeast: relevance to cancer therapy. Drug Resist Updat. 1998;1(3):176-83. doi: 10.1016/s1368-7646(98)80037-x. PMID: 17092803.
Copy Download .nbib Format: NLM
Andrographolide: a new plant-derived antineoplastic entity on horizon.

Evidence-based complementary and alternative medicine : eCAM

Varma A, Padh H, Shrivastava N.
PMID: 19752167
Evid Based Complement Alternat Med. 2011;2011:815390. doi: 10.1093/ecam/nep135. Epub 2011 Feb 10.

Plant-derived natural products occupy an important position in the area of cancer chemotherapy. Molecules such as vincristine, vinblastine, paclitaxel, camptothecin derivatives, epipodophyllotoxin, and so forth, are invaluable contributions of nature to modern medicine. However, the quest to find out...

Cite
Varma A, Padh H, Shrivastava N. Andrographolide: a new plant-derived antineoplastic entity on horizon. Evid Based Complement Alternat Med. 2011;2011:815390doi: 10.1093/ecam/nep135.
Varma, A., Padh, H., & Shrivastava, N. (2011). Andrographolide: a new plant-derived antineoplastic entity on horizon. Evidence-based complementary and alternative medicine : eCAM, 2011815390. https://doi.org/10.1093/ecam/nep135
Varma, Astha, et al. "Andrographolide: a new plant-derived antineoplastic entity on horizon." Evidence-based complementary and alternative medicine : eCAM vol. 2011 (2011): 815390. doi: https://doi.org/10.1093/ecam/nep135
Varma A, Padh H, Shrivastava N. Andrographolide: a new plant-derived antineoplastic entity on horizon. Evid Based Complement Alternat Med. 2011;2011:815390. doi: 10.1093/ecam/nep135. Epub 2011 Feb 10. PMID: 19752167; PMCID: PMC3139959.
Copy Download .nbib Format: NLM
Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Ha SW, Kim YJ, Kim W, Lee CS.
PMID: 19885006
Korean J Physiol Pharmacol. 2009 Apr;13(2):115-21. doi: 10.4196/kjpp.2009.13.2.115. Epub 2009 Apr 30.

Functional defects in mitochondria are involved in the induction of cell death in cancer cells. We assessed the toxic effect of camptothecin against the human cervical and uterine tumor cell line SiHa with respect to the mitochondria-mediated cell death...

Cite
Ha SW, Kim YJ, Kim W, et al. Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa. Korean J Physiol Pharmacol. 2009;13(2):115-21doi: 10.4196/kjpp.2009.13.2.115.
Ha, S. W., Kim, Y. J., Kim, W., & Lee, C. S. (2009). Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 13(2), 115-21. https://doi.org/10.4196/kjpp.2009.13.2.115
Ha, Sang Won, et al. "Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa." The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology vol. 13,2 (2009): 115-21. doi: https://doi.org/10.4196/kjpp.2009.13.2.115
Ha SW, Kim YJ, Kim W, Lee CS. Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa. Korean J Physiol Pharmacol. 2009 Apr;13(2):115-21. doi: 10.4196/kjpp.2009.13.2.115. Epub 2009 Apr 30. PMID: 19885006; PMCID: PMC2766704.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 433 entries